Reaction

Lung Cancer Metastatic reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,839 reports · 52 co-occurring drugs

As of the last recalculation, Lung Cancer Metastatic appears in 2,839 FAERS reports alongside 52 co-occurring drug terms. The strongest observed disproportionality signal is ERLOTINIB HYDROCHLORIDE (PRR 29.2).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Erlotinib Hydrochloride	49	29.2	29.3
Erlotinib	31	23.7	23.8
Crizotinib	35	20.4	20.5
Dalteparin Sodium	20	14.0	14.0
Pemetrexed	39	13.5	13.5
Pemetrexed Disodium	68	13.4	13.4
Abacavir Sulfate	14	10.6	10.6
Gefitinib	12	9.8	9.8
Efavirenz	13	8.6	8.6
Clozapine	140	8.5	8.6
Fondaparinux Sodium	8	7.3	7.3
Osimertinib	31	7.2	7.2
Iron Sucrose	8	6.2	6.2
Aprepitant	15	6.0	6.0
Romiplostim	12	5.9	5.9
Dronabinol	6	5.5	5.5
Zoledronic Acid	27	5.0	5.0
Carboplatin	84	5.0	5.0
Tranexamic Acid	6	5.0	5.0
Nicotine Polacrilex Mini	10	4.9	4.9
Nicotine Polarilex	10	4.9	4.9
Gemcitabine	25	4.7	4.7
Baricitinib	6	4.6	4.6
Ado-Trastuzumab Emtansine	5	4.4	4.4
Romosozumab-Aqqg	8	4.3	4.3
Memantine	8	4.3	4.3
Memantine Hydrochloride	8	4.3	4.3
Cisplatin	45	4.3	4.3
Infliximab	123	4.3	4.3
Nintedanib	18	4.2	4.2
Tolvaptan	8	4.0	4.0
Atezolizumab	20	3.8	3.8
Diroximel Fumarate	6	3.7	3.7
Gemcitabine Hydrochloride	26	3.6	3.6
Panitumumab	6	2.8	2.8
Bosentan	19	2.8	2.8
Docetaxel Anhydrous	25	2.7	2.7
Docetaxel	25	2.7	2.7
Risankizumab-Rzaa	29	2.6	2.6
Durvalumab	7	2.5	2.5
Alpelisib	3	2.5	2.5
Vismodegib	3	2.5	2.5
Lapatinib	5	2.4	2.4
Ranibizumab	8	2.2	2.2
Leuprolide Acetate	23	2.2	2.2
Dimethyl Fumarate	32	1.9	1.9
Dalfampridine	18	1.8	1.8
Natalizumab	44	1.8	1.8
Ranitidine Hydrochloride	13	1.8	1.8
Pirfenidone	9	1.6	1.6
Aflibercept	6	1.4	1.4
Droxidopa	4	1.4	1.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.